NanoVibronix's subsidiary receives patent approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 04 2025
0mins
Should l Buy ?
Patent Issuance: NanoVibronix's subsidiary, ENvue Medical, received U.S. Patent No. 12,402,953 B2 on September 2, which protects a method for overlaying electromagnetic navigation data onto real-time medical imaging.
Technological Impact: The patented technology aims to assist clinicians in visualizing the live path of feeding tubes or catheters on medical images, enhancing procedural accuracy and safety.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
